Latest Piperazines Stories
LEXINGTON, Massachusetts, January 26, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the United States Food and Drug Administration (FDA) has granted
As off-label antipsychotic use is mounting so, too, is litigation associated with specific atypical antipsychotics Port Washington, New York (PRWEB) January
RALEIGH, N.C., Jan. 8, 2015 /PRNewswire/ -- Sprout Pharmaceuticals will participate in the 33rd Annual J.P. Morgan Healthcare Conference to be held January 12 - 15, 2015, in San Francisco.
DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S.
RALEIGH, N.C., Jan. 6, 2015 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Cindy Whitehead has been named CEO, effective immediately.
-- Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the
WILMINGTON, Del., Dec. 19, 2014 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA(TM) (olaparib) capsules.
HPPI to commence Phase IIb study in first quarter 2015 of SUBA(TM)-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome TAMPA, Fla.
Geodon's drug label has been modified to warn of drug reactions with eosinophilia and systemic symptoms (DRESS); patients taking Geodon experiencing a fever with a rash and/or swollen lymph
DUBLIN, Dec. 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it is filing an emergency appeal to the U.S.